Tecarfarin
Tecarfarin is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 2 | 1 | — | — | 2 |
| Thrombosis | D013927 | — | — | 1 | — | — | 1 | ||
| Thromboembolism | D013923 | HP_0001907 | — | — | 1 | — | — | 1 | |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 1 | — | — | 1 |
| Atrial flutter | D001282 | EFO_0003911 | — | 1 | 1 | — | — | 1 | |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TECARFARIN |
| INN | tecarfarin |
| Description | Tecarfarin is a vitamin K antagonist under development for use as an anticoagulant. A Phase II/III clinical trial in 607 people, comparing it to the established vitamin K antagonist warfarin, found no difference in quality of anticoagulation or side effects between the two drugs in the overall population. Among patients taking CYP2C9 interacting drugs however, the tecarfarin patients’ TTR was 72.2% (n=92) vs 69.9% (n=87) for warfarin patients (pint=0.16); among patients who had both a CYP2C9 variant allele and taking a CYP2C9 interacting drug, TTR was 76.5% and 69.5% for the tecarfarin (n=24) and warfarin (n=31) groups, respectively (pint=0.24). This study included in 84 (14%) patients with a mechanical heart valve as an indication for anticoagulation therapy. No thrombotic or embolic events were observed in the tecarfarin treated subjects. In contrast to warfarin, tecarfarin is not affected by the cytochrome P450 inhibiting drug fluconazole, indicating a lower potential for interactions with other drugs.
|
| Classification | Small molecule |
| Drug class | warfarin analogs |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(OC(=O)c1ccc(Cc2c(O)c3ccccc3oc2=O)cc1)(C(F)(F)F)C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 867257-26-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105664 |
| ChEBI ID | — |
| PubChem CID | 54718618 |
| DrugBank | DB12823 |
| UNII ID | WN1479YT50 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more